# Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Study · id `cardio:ct-nct04177680` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04177680](<https://clinicaltrials.gov/study/NCT04177680>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04177680

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT04177680. Randomized; no masking; primary purpose treatment. Start 2020-06-03 (actual); primary completion 2020-11-27 (actual). Results posted on 2022-03-04.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Started: 2020-06-03 (actual) (ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Primary completion: 2020-11-27 (actual) (ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Completion: 2021-01-18 (actual) (ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Results first posted: 2022-03-04 (ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04177680, source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04177680-2022-03-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
- Acronym: ENHANCE-IT
- Condition: Hypertriglyceridemia
- Intervention (Drug): Omega 3 pentaenoic acid
- Intervention (Drug): icosapent ethyl
- Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Matinas Biopharma, Inc
- Collaborator class: INDUSTRY
- Collaborator: Midwest Biomedical Research
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry intervention name matches this record: Icosapent ethyl (`cardio:icosapent-ethyl`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study (`cardio:pubmed-35232215`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b27b94a0de12173a479d567ddd54c9639594d6d0dfc5730fcc7485c762c9bdf2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
